Sulfagenix licensed its lead product for marketing as a medical food and expects to enter the market in mid-2016. Funds are now being raised to provide funds for product launch, conducting a 200 patient open label heart failure study, which will include patient with preserved ejection fraction, and to achieve positive cash flow. The Company believes this strategy will reduce risks will retaining upside potential for its investors.